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ABSTRACT
African trypanosomosis is a major parasitic disease which affects both humans and animals in the Africa 
continent, south of the Sahara desert. It is caused by infection with various species of trypanosome that are 
transmitted to the host through the bite of an infected vector, the tsetse fl y. Efforts to control the disease have 
involved attempts to reduce the vector population by use of traps, insecticide application, the sterile male 
technique as well as treatment and prophylaxis of overt cases with chemotherapeutic drugs, consisting mainly 
of isometamidium, homidium, quinapyramine and diminazene. These drugs have been in use for over 50 years 
and are associated with severe toxicity and parasite resistance. Over the years, efforts in several laboratories 
to formulate new treatment profi les through pharmacokinetic studies of the trypanocides, combination 
therapy, use of medicinal plants and application of antioxidants, have not succeeded in eradicating the threat 
of the disease. The development of an effective vaccine has also not been successful due to the antigenic 
variation of the trypanosome surface coat, a condition that has stifl ed progress, if not totally halted vaccine 
development. However, more recent studies suggest the trypanosomal microtubulin could be a viable antigen 
for vaccine development. This review focuses on measures that have been undertaken to control Animal African 
Trypanosomosis by chemotherapy, and discusses future measures and prospects since the measures adopted so 
far have not successfully controlled the disease. 
Key words: chemotherapy; trypanosomosis; control measures; sanative pair; combination therapy; 
medicinal plants; antigenic variation; tubulin antigen________________________________________________________________________________________
Introduction 
Preamble
African trypanosomosis is a disease complex of both humans and animals in the 
African continent, south of the Sahara. It is caused by infection with various species 
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of blood and tissue dwelling protozoan parasites of the genus Trypanosoma, that are 
transmitted by multiple species of the tsetse fl y (Glossina spp.) which inhabit about half 
the non-desert area of Africa. Animal species vary in their susceptibility to the different 
species of trypanosomes. Cattle, sheep and goats are most commonly infected by T. 
congolense (GROOTENHUIS et al., 1990; SAMDI et al., 2011), T. vivax (WELLDE 
et al., 1989; KIMETO et al., 1990), and T. brucei brucei (WELLDE et al., 1989). 
Trypanosoma simiae is the major cause of infection in pigs (ONAH, 1991). Horses are 
infected by T. equiperdum (SNOW et al., 1996; FAYE et al., 2001), causing a form of 
the disease called “dourine” which is sexually transmitted. Horses have been observed to 
be infected by T. congolense, T. b. brucei and T. vivax with an infection rate of 31% for 
T. congolense, 87% for T. vivax and 18% for T. brucei sp. (SNOW et al., 1996; FAYE et 
al., 2001; DHOLLANDER et al., 2006; PINCHBECK et al., 2008). Trypanosoma evansi 
causes surra in a wide variety of wild and domestic animals, including equines, camels, 
goats, sheep, cattle, buffaloes, pigs, dogs, tigers and elephants (GUTIERREZ et al., 2008; 
RATHORE et al., 2016). Trypanosoma evansi is mechanically transmitted by blood-
sucking fl ies, such as Tabanus and Stomoxys species, and its ability to infect human 
beings has been reported (RATHORE et al., 2016). Chickens are naturally resistant to the 
disease (JOSHUA, 1982). In humans, T. brucei rhodesiense is responsible for an acute 
form of trypanosomosis in Eastern and Southern Africa (FEVRE et al., 2005), while T. 
b. gambiense causes a chronic form in West and Central Africa (SMITH et al., 1998; 
MAUDLIN, 2006). Sporadic reports have appeared of other trypanosome species causing 
the disease in humans. These include T. congolense (TRUC et al., 1998) and T. evansi 
(JOSHI et al., 2005; WABALE et al., 2015; CHAU et al., 2016). Trypanosoma barrettoi 
has been isolated from the blood of fi sh (LOPES et al., 1990). Animal reservoirs play an 
important role in the epidemiology of both animal and human trypanosomosis (NJIOKOU 
et al., 2006; SIMO et al., 2006). Wild animals can also suffer from trypanosomosis, 
although they generally have greater tolerance to the disease than domestic animals. 
Animal African trypanosomosis has been a major constraint to agricultural production 
in about 10 million Km2 of sub-Saharan Africa (LUCKINS, 1992; ILRI, 1996). Over 40 
million head of Africa’s cattle population are kept in tsetse infested areas (BUDD, 1999). 
Cattle living in areas where trypanosomosis is endemic are 20% less productive in terms 
of meat and milk production than herds living in tsetse and trypanosomosis-free areas 
(BUDD, 1999). It has been estimated that direct losses due to trypanosomosis, in the areas 
of meat, milk, traction power, and control programs, amount to US$ 500 million and indirect 
losses resulting from the inability to keep livestock and grow food because of poor human 
health, amount to US$ 5 billion per annum (ILRI, 1997). 
Concerted efforts to control trypanosomosis have been going on over the past century 
(DREWS, 2004). Numerous methods of control have been developed, yet the disease has 
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proved very diffi cult to eradicate. Ironically, trypanosomes were among the fi rst organisms 
to be targeted by synthetic drugs. Paul Ehrlich, ‘the father of chemotherapy’, chose these 
organisms as a model on which to test his ideas (DREWS, 2004). Chemotherapy has 
been a major component in the control of trypanosomosis but no new trypanocide has 
been introduced into the fi eld since the early 1960s (ONYIAH, 1997). This is partly 
because of the prohibitive cost of discovering, developing and introducing new drugs 
onto the market (GEERTS et al., 2001; LINARES et al., 2006). For instance, in 1975, 
the $1 billion spent on drug research and development in the USA yielded only seven 
drug entities, in sharp contrast to the situation in the 1950s in which about forty new 
drug entities were introduced yearly, with a total annual research and expenditure of 
less than $100 million (TROUILLER and OLLIARO, 1999). This situation is partly due 
to the scope of testing required by the regulatory bodies, with the consequent increase 
in expenditure. The huge capital required by the developed economies to develop new 
trypanocides is regarded as hardly worth it because the political and economic situations 
in the countries where trypanocides are required are not encouraging (MURGOLO et 
al., 1989; GEERTS et al., 2001). Human African trypanosomiasis (HAT) has thus been 
classifi ed as a neglected disease (REMME et al., 2002). BARRETT et al., (2007) defi ne 
neglected diseases as those ailments which affect people from among the world’s poorest 
populations, for which satisfactory treatment does not exist, but for which the investment 
required to bring new compounds to the market has proven a major disincentive to drug 
development. 
Chemotherapy of trypanosomosis
Chemotherapy and chemoprophylaxis of animal trypanosomosis rely on the use of 
trypanocidal drugs. They are the mainstay of trypanosomosis control measures (ONYIAH, 
1997; BARRETT et al., 2007) and will probably remain so for a long time, in spite of the 
problems of drug resistance and toxicity (ROSS and TAYLOR, 1990; GEERTS et al., 2001; 
BALDISSERA et al., 2016a) because drugs are the only method of control readily available 
to individual farmers. 
The drugs currently in use in animal trypanosomosis include: diminazene aceturate 
(Berenil), isometamidium chloride (Samorin), homidium chloride (Novidium), homidium 
bromide (Ethidium), quinapyramine methylsulfate (Antrycide), and quinapyramine 
methylsulfate/chloride (Antrycide prosalt). Of these, only Berenil and Samorin are 
commonly available. Berenil is used exclusively as a therapeutic agent, while Samorin has 
both prophylactic and curative properties. Homidium has limited prophylactic properties. 
Table 1 shows the list of drugs that have been used in the treatment of Animal African 
Trypanosomosis (AAT). These trypanocides have been in use for over 50 years. Today, 
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parasite resistance to these drugs is widely reported (AFEWERK et al., 2000; ANENE et al., 
2001; KAGIRA and MAINA, 2007; SHIFERAW et al., 2015). 
A relatively new, water-soluble trivalent arsenical agent, melarsamine hydrochloride, 
has been evaluated as a trypanocide. Melarsamine hydrochloride is a melaminophenylarsine 
compound made by conjugation of one equivalent of melarsen oxide and two equivalents of 
cysteamine. It was patented in 1985 under the trade name Cymelarsan (Rhone Merieux, 
France). It has been shown to be very effective against T. brucei brucei, T. evansi, and 
T. equiperdum in camels, buffalo, goats, and pigs (LUN et al., 1991; OTSULYA et al., 
1992; ZWEYGARTH et al., 1992). YOUSSIF et al. (2008) reported that cymelarsan was 
effective at a single dose of 0.25-0.625 mg/kg in Nubian goats infected with T. evansi. 
The authors also observed that the single dosage of 1.25 mg/kg and the multiple dosages 
were toxic and fatal, and that the drug has an accumulative effect. Cymelarsan was also 
found to be effective against diminazene aceturate-resistant T. brucei brucei and T. evansi 
(ZHANG et al., 1992). ANENE et al. (1999) evaluated the effi cacy of Cymelarsan, 
against T. brucei infection in mice and dogs, and observed improvements in their clinical 
condition as well as weight gains in treated dogs. On the basis of the results from the 
evaluation experiments, MelCy was licensed for use against trypanosomosis in animals. 
Recently, HAGOS et al. (2010) also found Cymelarsan to be quite effective in curing 
horses with the acute as well as the chronic form of dourine. 
Attempts at improving the effi cacy of trypanocidal drugs
In the absence of new drugs, it was deemed necessary by several researchers to 
formulate new treatment protocols to improve the effi cacy of the existing drugs. The goals 
have been to elucidate the pharmacokinetics of trypanocides; formulate an inexpensive, 
non-toxic, easy to administer chemotherapeutic drug, or to create a medium that would 
enhance the effi cacy of the existing trypanocides. Some of the foci of research included:
Pharmacokinetic studies on available trypanocides to improve our understanding and 
enable a reassessment of the dosages and treatment protocol.
Complexation of trypanocides with adjuvants.
The use of a sanative pair. 
The use of hyperosmolar agents to enhance drug distribution and penetration into the 
brain.
The use of combination therapy involving trypanocides, antioxidants and natural 
products. 
Pharmacokinetic studies 
In line with the objective of a better understanding of the pharmacokinetics of 
trypanocides, and reassessment of dosages and treatment protocols, the pharmacokinetic 
profi le of diminazene aceturate (DMA) was intensively studied in several animal 
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species, including rabbits (GILBERT, 1983), monkeys (RAETHER et al., 1974), cattle 
(MAMMAN et al., 1993; ALIU et al., 1993), dogs (ONYEYILI and ANIKA, 1989, 1991), 
goats (ALIU et al., 1984; ONYEYILI et al., 2002), sheep (ALIU and ǾDEGAARD, 
1985), and rats (ODIKA et al., 1995). Absorption of diminazene aceturate through the 
oral route has been recorded in some animal species, including rats (RAETHER et al., 
1974; KELLNER et al., 1985) and monkeys (RAETHER et al., 1974).
It was observed that DMA (3.5 mg/kg) administered intravenously to mongrel 
dogs after infection with T. congolense was rapidly distributed in the body. However, 
the infection had no marked infl uence on the urinary excretion of the drug, whereas 
intravenous administration of DMA 3.5 mg/kg in T. b. brucei infected mongrel dogs 
signifi cantly altered the kinetic disposition of DMA (ONYEYILI and ANIKA, 1989). 
The distribution half-life of the drug was markedly decreased and there was a prolonged 
elimination half-life, with a decreased total body clearance in the infected animals. These 
observations were attributed to the pathological changes in the cardiovascular system 
induced by trypanosomal infection. The tissue distribution and residue profi le of DMA 
(3.5 mg/kg) was also investigated in healthy dogs, and in dogs infected with T. congolense 
and T. b. brucei treated intramuscularly (ONYEYILI and ANIKA, 1991). Diminazene 
was observed to be distributed to various organs and tissues of the body, with the highest 
concentrations occurring in the liver and kidneys. Higher drug levels were found in the 
tissues of healthy dogs when compared with those of trypanosome infected animals, 
except in the brain. Drug residues were still detectable in the tissues of the animals 10 
days after drug administration (ONYEYILI and ANIKA, 1991). 
In another study, the effect of chlorpromazine (CPZ) on the tissue distribution of 
DMA was also investigated in rabbits. There was a delay in the attainment of peak 
concentration in the rabbits treated with DMA (7mg/kg, intramuscular) and CPZ (5mg/kg, 
intramuscular). High levels of DMA occurred in the brain of rabbits given a combination 
of CPZ and DMA compared to the level obtained in the rabbits given DMA alone. This 
indicates the greater penetration of DMA into the central nervous system of the rabbits 
that received a combination of CPZ and DMA (ONYEYILI et al., 1992).
With regards to isometamidium (ISMD), BRAIDE and EGHIANRUWA (1980) 
reported that drug levels were detected in goat plasma 24 hours after intramuscular 
injection, but not after intravenous injection. These authors attributed this observation to its 
rapid distribution from the systemic circulation. ISMD concentrations were also detected 
in appreciable levels in the liver and kidneys, 12 weeks after intravenous administration. 
No drug concentration was detected in the muscles, except at the intramuscular site of 
injection. The authors attributed the prophylactic action of the drug to this intramuscular 
depot, which becomes limited following encapsulation resulting from local tissue 
reaction (ALIU and CHINEME, 1980). As a result of the known tissue reaction of ISMD 
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at the intramuscular site of injection, OGUN and EGHIANRUWA, (1993) evaluated 
the absorption rate of ISMD from the stomach and intestine of rats, and reported that 
ISMD was appreciably absorbed from the stomach and not from the intestine. In a 
comparative effi cacy study of ISMD following intramuscular and oral administrations, 
the intramuscular route was found to be clearly superior (EGHIANRUWA et al., 2004).
Complexation of trypanocides
Complexes of ISMD with adjuvants have also been produced to alter the kinetic profi le 
of ISMD. Studies involving the Isometamidium-dextran complex and isometamidium-
suramin complex were undertaken in the late seventies and early eighties (JAMES, 1978; 
ALIU and SANNUSI, 1979; ALIU and CHINEME, 1980), following the suggestion that 
complexation would alter the kinetics of absorption and lengthen the prophylactic period. 
The results of the studies showed that the amount of isometamidium-dextran complex 
containing an equivalent of the therapeutic dose of uncomplexed drug extended the 
period of effective prophylaxis by several months in both rats and mice (JAMES 1978). 
Following studies on the isometamidium-dextran complex, ALIU and SANNUSI, (1979) 
concluded that the complex, at a 1 or 2 mg/kg subcutaneous injection, could be expected 
to protect cattle against trypanosomosis and still yield good carcass and hide grading. 
The therapeutic index of the isometamidium-dextran complex was four times that of 
isometamidium alone (ALIU and CHINEME (1980). The subcutaneous site of injection 
of the complex tolerated a higher dose of isometamidium, with a resultant increase in the 
prophylactic period (ALIU and SANNUSI, 1979; ALIU and CHINEME, 1980).
FLUCK and HOPKINS (1988), incorporated Diminazene, homidium and 
isometamidium into liposomal formulations, with a view to prolonging their activity 
and improving tolerance. The authors observed no adverse effects after administration 
of the phospholipid complexes as multilamellar liposomes, but reported that the reaction 
at the intramuscular injection site to liposomal isometamidium was markedly less than 
the reaction to a isometamidium solution, even though the liposomal preparations did not 
substantially enhance the duration of the prophylaxis of the three compounds.
The use of a sanative pair
This concept, which was fi rst suggested by WHITESIDE (1962), prescribes the 
sequential use of a pair of chemically unrelated trypanocides (e.g. Berenil and Homidium). 
The concept entails the use of one of the sanative pair until resistant strains of trypanosomes 
appear, following which the second is substituted and used until the resistant strains have 
disappeared from cattle and tsetse. A modifi ed version of this concept ultimately became 
the trypanosomosis drug policy of the then Northern Region of Nigeria. The drug policy 
prescribed that each of the two curative drugs be used for six months of the year when a 
species of trypanosomes sensitive to the drug was predominant (ILEMOBADE, 1979). 
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For example, T. vivax was found to be generally susceptible to homidium compounds 
and was the predominant species in cattle when they were withdrawn to the wet-season 
grazing areas; whereas T. congolense was generally susceptible to berenil and was the 
predominant species in cattle during the dry season when cattle were moved to pastureland 
in the tsetse belts of the south. However, this treatment regime was rather short lived, as 
isolates of T. congolense and T. vivax with multiple resistance to curative trypanocides 
were isolated and subsequently found to be widespread.
Hyperosmolar agents and relapse infections
Poor drug distribution to infected tissues, particularly the brain, is one of the host 
related factors associated with relapse of trypanosomosis infection (JENNINGS et al., 
1979). Diminazene aceturate, the routine drug for treating trypanosomosis in Nigeria, has 
small molecular size but its charged nature prevents easy passage across the blood-brain-
barrier (BBB), with the result that in cerebral trypanosomosis, the trypanosomes evade 
its trypanocidal action. In order to overcome this failure to reach the required therapeutic 
concentrations at the parasite location in the brain, hyperosmolar agents such as lithium 
chloride (LiCl) and sucrose were used in combination with trypanocides, to achieve the 
osmotic opening of the BBB and the resultant effective chemotherapy. Lithium chloride 
and sucrose are known to effectively open the BBB (SPATZ et al., 1976).
Intramuscular lithium chloride (10 mg/kg) caused a signifi cant increase in the brain 
concentration of DMA (3.1 mg/kg im). The addition of sucrose (1.0 g/kg im) was not as 
effective. The DMA levels were also signifi cantly higher in the organs (brains, kidney, 
liver and spleen) of trypanosome infected rats compared to those uninfected (ODIKA et 
al., 1995). Furthermore the concentration of DMA in the organs increased signifi cantly 
(P<0.05) with increasing concentrations of LiCl (ODIKA et al., 1995).
Combination therapy
It has been suggested that the low effi cacy of trypanocides may result from under-dosing, 
poor drug quality, rapid-infection with short-acting therapeutic agents (such as DMA) and 
drug resistance. To exclude the possibilities of under-dosing and poor drug quality, samples of 
DMA and isomethamedium chloride obtained locally were analyzed, and the results showed 
that the qualities were of acceptable standards. This result thus suggested the existence of 
genuine drug resistance in the fi eld (ANENE et al., 1996).
In order to address the problem of drug resistance, a study was conducted in vitro to assess 
the ability of calcium antagonists of several chemical classes (verapamil, cyproheptadine, 
desipramine and chlorpromazine) to reverse resistance of Trypanosoma evansi to a range 
of trypanocides including DMA, suramin and MelCy. The putative resistance modulators 
were intrinsically antitrypanosomal, but were unable to reverse resistance to any of the 
trypanocides tested (ANENE et al., 1996).
254 Vet. arhiv 88 (2), 245-270, 2018
K. I. Eghianruwa et al.: Chemotherapeutic control of trypanosomosis 
- a review of past measures, current status and future trends
Again, because most of the available trypanocides in use were developed over 5 
decades ago, it was perceived that their long usage and misuse may have encouraged the 
development of drug resistant parasites. A study was thus conducted to assess the effi cacy 
of Difl uoromethylornithine (DFMO, efl ornithine), a newly introduced human trypanocide 
in the treatment of both primary and relapse infections of Trypanosoma brucei in dogs. 
Simultaneous administration of DFMO intravenously and single dose of diminazene 
(7mg/kg) in primary infections achieved a higher chemotherapeutic level compared to the 
monotherapy, as no relapses occurred (ANENE et al., 1997).
The suggestions of some authors (IGBOKWE, et al., 1998; UMAR et al., 2000; 
IHEDIOHA and ANWA, 2002) of the possible involvement of Reactive Oxygen Species 
(ROS) in the pathogenesis of trypanosomosis prompted the evaluation of the effi cacy 
of diminazene aceturate alone and in combinations with antioxidants (ascorbic acid, 
dimethyl sulfoxide, tocopherol and selenium) in experimental murine T. brucei and T. 
congolense infections. Results from these studies were variable, with both the species of 
trypanosome and antioxidants. When considered in totality, antioxidant supplementation 
following diminazene injection showed superiority over diminazene alone in reversing 
the pathological conditions caused by trypanosome infection (EGHIANRUWA et al., 
2009, EGHIANRUWA and ANIKA, 2010, 2011, 2012; EGHIANRUWA and OBIDIKE, 
2011; EGHIANRUWA, 2012). 
An overview of the many efforts made to obtain better therapeutic results from drug 
treatment of overt trypanosomosis cases showed that these treatments relieved the animals 
temporarily of the parasitaemia. No treatment protocol had the desired prolonged and 
lasting effect. Moreover, the issue of relapse and drug resistance could not be resolved.
Future trends in the chemotherapy of trypanosomosis
Development of new drugs
One of the most signifi cant problems faced in controlling the spread of trypanosomosis 
is that there is little economic incentive to conduct research in these impoverished parts of 
the world that are endemic to the disease, and it is diffi cult to get expensive drugs to the 
people. The drug discovery scenario, however, is changing dramatically. Several potential 
drug targets and molecules have been recognized. 
One of the drug targets identifi ed so far is related to an unusual enzyme, Trypanosome 
Alternative Oxidase (TAO) which T. brucei uses in glycolysis. This enzyme is the 
terminal oxidase of the respiratory chain of long slender bloodstream forms of the African 
trypanosome, and it is absent from the host (NIHEI et al., 2002; CHAUDHURI et al., 
2006). The amino acid sequence of TAO in HAT-causing trypanosomes was observed 
to be identical to that in non-human infective T. b. brucei (NAKAMURA et al., 2010). 
As an essential factor for trypanosome survival, TAO is a promising drug target in both 
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human and animal Africa trypanosomes, due to the absence of alternative oxidases in 
the mammalian host. Ascofuranone, a compound isolated from the phytopathogenic 
fungus Ascochyta visiae, has been shown to be the most potent inhibitor of TAO to date 
(NIHEI et al., 2002). NAKAMURA et al. 2010 reported that ascofuranone, quickly 
kills trypanosomes in vitro and cures mice infected with T. b. brucei. The potential of 
Cathepsin (CATL), a lysosomal cysteine peptidase, as an important potential drug target 
in trypanosomes has also been suggested (ALSFORD et al., 2014).
KALIDAS and PHILIPS (2012) reported systematic analysis of approximately 200 
genes coding for enzymes involved in different biochemical and signaling pathways, 
by RNA interference (RNAi) knockdown or gene knockout. RNA interference is a 
phenomenon through which double stranded RNA (dsRNA) induces potent sequence-
specifi c degradation of homologous transcripts, and it has emerged as an invaluable tool 
for elucidation of gene function and drug target validation (VINCENT et al., 2008). 
Using a newly developed vector (pTrypRNAiGate), KALIDAS and PHILIPS 2012, have 
knocked down seven aminoacyl tRNA synthetases (AARS), which have an important 
role in protein translation. RNAi against fi ve AARS resulted in growth inhibition of the 
T. brucei bloodstream forms in vitro.
It is well established that the bloodstream forms of trypanosomes in a patient have 
a coat of variant surface glycoprotein (VSG) that shields them from the immune system 
(TAYLOR and RUDENKO, 2006). However, the procyclic forms, which are the fi rst 
life-cycle stage to develop in the tsetse fl y, replace the VSG coat by procyclins that do not 
protect the parasite from lysis by serum components. This process of differentiation from 
bloodstream to procyclic forms is specifi c to the parasite and has been exploited by some 
workers to screen for potential drug candidates (WENZLER et al., 2016). 
The prospects for exploiting differences between parasite and mammalian protein 
kinases to develop new trypanocides have been reported (NAULA et al., 2005). Protein 
kinase regulates many different cellular processes, such as transcriptional control, cell 
cycle progression and differentiation (WIESE et al., 2003; ELLIS et al., 2004) and its 
potential as drug targets is not restricted to trypanosomosis but also to a wide range of 
diseases and syndromes, such as cancer, cardiovascular disease and Alzheimer’s disease 
(SEBOLT-LEOPOLD and HERRARA, 2004; NAULA et al., 2005; STRUMBERG and 
SEEBER, 2005).
Some researchers have suggested that one approach to fi nding new drugs and 
rediscovering old ones is based on enzyme inhibitors that paralyze antioxidant systems, 
which are essential to the parasites as they are attacked in the host by reactive oxygen 
species, such as peroxynitrite, hypochlorite, and H2O2 (KRAUTH-SIEGEL et al., 2005). 
The antioxidant system of the trypanosome is thought to consist of some 20 thiol and 
dithiol proteins centered around the unique dithiol trypanothione. Several workers have 
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considered this antioxidant system as a potential drug target in trypanosomes (BUDDE and 
FLOHE, 2003; KRAUTH-SIEGEL et al., 2005; JAEGER and FLOHE, 2006). Evidence 
from gene disruption studies indicates that trypanothione and other low molecular mass 
thiols are directly or indirectly maintained in a reduced state by trypanothione reductase, 
an apparently essential enzyme, which appears to be unique to this genus (KRIEGER 
et al., 2000; BEIG et al., 2015). Blocking the synthesis of trypanothione could be a 
useful pathway for developing a drug which would kill the parasites without harming the 
human host. KRIEGER et al. (2000), reported that trypanosomes lacking trypanothione 
reductase are avirulent and show increased sensitivity to oxidative stress. Competitive 
and irreversible inhibitors of the enzyme have been designed, and some have been tested 
following attempts to exploit trypanothione reductase as a chemotherapeutic target 
(STEENKAMP, 2002; STUMP et al., 2007; RICHARDSON et al., 2009; BELLUTI et 
al., 2014).
Evidence from literature indicates that signifi cant advances are being made in the 
search for new drugs, especially against Human Africa Trypanosomosis. Further studies 
will be required to ascertain the activities of these new drugs in treating Animal Africa 
Trypanosomosis.
Improved drug delivery to target sites in the parasite
Drug resistance and the low therapeutic index of available trypanocides have been 
some of the limiting factors to the effective control of trypanosomosis by chemotherapy 
(DELESPAUX and De KONING, 2007). One mechanism by which trypanosomes 
develop resistance is by alteration of the nucleoside transporter system associated 
with the movement of drug molecules to target sites within the parasite (SHIFERAW 
et al., 2015). Resistant populations of trypanosomes are known to take and accumulate 
less trypanocides than sensitive ones (SUTHERLAND et al., 1992; MULUGETA 
et al., 1997). While the search for new drugs is ongoing, efforts to develop new drug 
formulations, that would improve drug delivery to target sites within the parasite with 
consequent increases in effi cacy and safety, are equally being pursued. Studies are 
ongoing in several laboratories on the application of nanotechnology in the development 
of drug delivery systems to treat parasitic diseases. Nanoparticle based drug delivery 
systems possess the advantage of improved effi ciency, arising from their ability to deliver 
the drug to the required target. Effi cient drug delivery is also associated with reduced 
toxicity, prolonged drug effect, improved stability of therapeutic agents and reduction 
in drug dose (SINGH and LILLARD, 2009). The benefi t of nanoparticle-coupled drugs 
in drug targeting has been realized in cancer therapy, where such drugs act specifi cally 
on the cancer cells (De JONG and BORM, 2008). Some reports are available on the 
advantages of nanoparticle-coupled drugs in trypanosomosis. UNCITI-BROCETA 
et al. (2015) using nanoparticles of chitosan loaded with pentamidine and coated by a 
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single domain nanobody that specifi cally targets the surface of African trypanosomes, 
and have reported a 100 fold reduction in curative dose compared to pentamidine alone. 
These authors also reported that pentamidine loaded onto chitosan was active against 
a trypanosome cell line known to be resistant to pentamidine, due to mutations in the 
surface transporter. The higher effi cacy of the chitosan-pentamidine formulation was 
associated with improved entry of pentamidine into trypanosomes through endocytosis, 
instead of via the classical cell surface transporters (UNCITI-BROCETA et al., 2015). 
The nanoparticle delivery system has also been extended to natural products, such as 
nerolidol, that possess antitrypanosomal actions. Nerolidol is an aliphatic sesquiterpene 
alcohol present in the essential oils of many plants with proven in vitro activity against 
T. evansi (MOHD-SHUKRI and ZAINAL-ABIDIN, 2011; BALDISSERA et al., 2016b). 
Orally administered nerolidol-loaded nanosphere in T. evansi infected rats resulted in 
a survival rate of 66.66% compared to 0% when nerolidol was used alone, or 33.33% 
survival rate obtained with diminazene (BALDISSERRA et al., 2016b). Studies on 
nanoparticle drug delivery systems have witnessed vigorous activity and expectations are 
high. If the results obtained from pentamidine-loaded nanoparticles can be replicated in 
other aged trypanocides, the technology may well lead to the resurgence of the old drugs.
Medicinal plants and natural products as potential sources of trypanocidal drugs
It is a truth universally acknowledged that plants are important sources of medicines. 
Plants do not only contain active pharmacological principles, but their contents are also 
used as template molecules for the production of new drugs. Hence, the knowledge 
gained from the use of medicinal herbs and their active ingredients has served as the 
foundation for much of modern pharmacology, and many modern drugs have their origin 
in ethnopharmacology. Patronage of traditional based medical systems, in which higher 
plants constitute the main sources of drug therapy, has increased steadily over the past 
decade. Novel treatment strategies for the management of several disease conditions, such 
as diabetes and many forms of cancer, have emanated from herbal medicines (GURIB-
FAKIM and MAHOMOODALLY, 2013).
There is an abundance of reports in the literature from studies, both in vivo and in vitro, 
which have been conducted to investigate the effectiveness of traditionally used medicinal 
plants in alleviating the effect of trypanosomosis on the host (SALEM and WERBOVETZ, 
2006; MANN and OGBADOYI, 2012). HOET et al. (2004), reviewed 120 plant derived 
compounds, consisting of alkaloids, phenolic derivatives, quinones, terpenes and other 
metabolites, which reportedly possess activity against African trypanosomes (mainly 
Trypanosoma brucei subsp., T. congolense and T. vivax) in a submicromolar range, out 
of which 12 were shown to be relatively selective. Chemical modifi cation of natural 
products, such as ascididemin, neocryptolepine, tryptanthrin and diospyrin, resulted in 
more trypanosomal activities and less toxicity, again illustrating how natural products can 
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serve as a basis for developing derivatives with increased activity and/or lower toxicity 
(HOET et al., 2004).
Few natural products have been evaluated in rodent models of African trypanosomiasis. 
Some encouraging reports have been published (ASUZU and CHINEME, 1990; AKANJI 
et al., 2009; OMOJA et al., 2011; MANN and OGBADOYI, 2012). Ascofuranone, a 
prenylated phenol antibiotic and a structural analog of coenzyme Q isolated from a 
phytopathogenic fungus, Ascochyta visiae, resulted in 100% cure of mice infected with 
T. b. brucei when given by intraperitoneal route in combination with glycerol. The 
compound was reported to be highly non-toxic in vivo and able to cross the blood-brain 
barrier (MINAGAWA et al., 1997; YABU et al., 2003, 2006). Similarly, a fraction of the 
oily extract from garlic bulbs cured mice infected with T. b. brucei in four days, when 
given intraperitoneally at a dose of 120 mg kg-1 per day (NOK et al., 1996).
Thorough understanding of the mode of action of the pharmacologically active 
principles in natural products is still lacking. However, possible mechanisms have been 
suggested in some cases. For instance, NOK et al. (1996), attributed the action of the oily 
extract from garlic bulbs to its interference with the parasites’ synthesis of membrane 
lipids. Similarly, the mechanism of the action of ascofuranone, a structural analog of 
coenzyme Q, is attributed to its binding at the coenzyme Q site of ubiquinol oxidase, thus 
blocking trypanosome alternative oxidase (TAO), one of the two enzymes associated 
with a unique mitochondrial electron transport system in T. b. brucei bloodstream forms. 
Glycerol suppresses the second enzyme, glycerol-3-phosphate dehydrogenase, by mass 
action. Hence, it has been observed that inhibitors of TAO become trypanocidal when 
combined with glycerol, due to the total block of the energy production of bloodstream 
forms (NIHEI et al., 2002).
The gap in the complete knowledge of these promising antitrypanosomal natural 
products can be bridged by in-depth interdisciplinary investigations to elucidate their 
actions and identify new leads. The ultimate benefi t for trypanosome endemic areas 
would be to design inexpensive standardized medicines, following validation and 
identifi cation of the active principles in the plants used in traditional medicine to treat 
African trypanosomosis.
Vaccine production
Success has not been forthcoming in the production of vaccines against trypanosomosis. 
Studies have shown that bloodstream forms of trypanosomes circumvent the host immune 
response by continuous changes to surface glycoprotein, hence continuous changes in 
antigenicity. The variable surface glycoproteins (VSGs) are antigenically distinct due 
to extensive differences in the primary sequences (TAYLOR and RUDENKO, 2006; 
RUDENKO, 2011). Antigenic variation of the parasite has been seen as one of the 
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most spectacular adaptive mechanisms exhibited by the African trypanosomes, and the 
main reason why the development of vaccine has been elusive (MURRAY et al, 1979). 
The trypanosome has therefore been credited as the ultimate immune destroyer and 
escape artist (La GRECA and MAGEZ, 2011). A review of the various attempts made 
to vaccinate both domestic livestock and laboratory animals showed from the reported 
studies that complete protection was readily achieved only if the same variable antigen 
type (VAT) was used for immunization and challenge (GRAY, 1976; MURRAY et al., 
1979; TABEL et al., 2008). When a distant VAT was used for challenge, no protection 
occurred. Following these observations, many researchers in the area of trypanosomosis 
control have assumed that an effective vaccine would have to contain all VATS, possibly 
an insurmountable task as the number of VATS is likely to be large. Hence many consider 
the possibility of vaccination to be remote.
Although this view has been widely held and propagated, some workers have shown that 
failure to achieve effective vaccination to control trypanosomosis is due to factors other than 
antigenic variation (WEI and TABEL, 2008; WEI et al., 2011; TABEL et al., 2013). Studies 
have shown that antibodies to the VSG are required for the control of African trypanosomes 
infecting the blood, whereas infections of the skin by low numbers of trypanosomes are 
controlled by innate resistance and do not require antibodies for their control. Low numbers 
of trypanosomes infecting the skin, although killed by innate resistance, do not induce 
protection, but enhance susceptibility to re-infections due to suppression of the innate 
resistance by adaptive immune responses (MANSFIELD and PAULNOCK, 2005; WEI and 
TABEL, 2008; WEI et al., 2011; TABEL et al., 2013). These workers concluded that immune 
suppression, which is one of the cardinal effects of Trypanosomosis, is responsible for vaccine 
failure. DARJI et al. (1992) proposed that immune suppression is attributed to the coexistence 
of at least two unlinked suppressive mechanisms that block different T-cell regulatory steps 
and operate through different effector mechanisms, and the authors linked these mechanisms 
to the generation of prostaglandin-producing macrophages which are entirely responsible for 
the suppression of IL-2 production, whereas the induction of a prostaglandin-independent 
suppressive mechanism accounts for the suppression of the expression of IL-2 receptors (IL-
2R). This point of view had been expressed by other workers (SILEGHEM et al., 1989; 
SCHLEIFER and MANSFIELD, 1993). Following the results of their studies, TABEL et al. 
(2013) concluded that any attempt to produce an effective vaccine should fi rst address the 
problem of induction of immunosuppression by the trypanosomes. 
Continued efforts to develop effective vaccines have resulted in studies of other non-
variable molecules in the trypanosome. African trypanosomes express numerous non-
variable antigens (LUBEGA et al., 2002; RASOOLY and BALABAN, 2004; LI et al., 
2009). The fl agellar pocket has been of particular interest, as an organelle specialized in 
endocytosis and exocytosis, containing relatively well-conserved receptors (MKUNZA et 
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al., 1995; FIELD and CARRINGTON, 2009), cytoskeleton proteins (HUTCHINSON et 
al., 2004) and trypanosomal microtubulin (LUBEGA et al., 2002; LI et al., 2007). RASOOLY 
and BALABAN (2004) reported 100% protection from an otherwise lethal challenge of a 
heterologous strain of T. brucei when they used native or recombinant microtubule-associate 
protein (MAP p15) as a vaccine in mice. Similarly, LUBEGA et al. (2002), reported 60-80% 
protection by renatured T. brucei tubulin against T. brucei, T. congolense or T. rhodesiense 
challenge in mice, and that four out of fi ve mice, given passive immunity by the transfer of 
anti-nTbTub serum, were completely protected, while one of the fi ve was partially protected. 
LI et al., (2007) also reported 83.3%, 70% and 76% protection by renatured recombinant T. 
evansi beta-tubulin against strains of T. evansi, T. equiperdum and T. b. brucei, respectively. 
Serum collected from rabbits immunized with recombinant beta-tubulin inhibited the growth 
of T. evansi, T. equiperdum and T. b. brucei in vitro (LI et al., 2007). 
Conclusion
If trypanosomosis must be controlled relatively cheaply, vaccination still remains 
the best theoretical option. This is particularly expedient considering the fact that 
trypanosomosis affects poor economies and the cost of developing new effective drugs 
is exorbitant. There is little doubt that the introduction of an effective vaccine, if used 
strategically, along with improved treatment methods and tsetse control measures, would 
make an enormous contribution to the control of African trypanosomosis. This would 
be followed by increased human productivity and livestock production in endemic 
trypanosome areas of the African continent.
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SAŽETAK
Afrička tripanosomoza glavna je nametnička bolest ljudi i životinja na afričkom kontinentu južno od 
Sahare. Njezini su uzročnici različite vrste tripanosoma koje se prenose na domaćina ubodom zaraženog 
prijenosnika muhe ce-ce. Napori koji se ulažu u kontroli bolesti uključuju i pokušaje za smanjenje populacije 
prijenosnika uporabom klopki, primjenom insekticida, postupkom sterilnih mužjaka kao i liječenjem te 
profi laksom kemoterapeuticima poput izometamidija, homidija, kvinapiramina i diminazena. Ti su lijekovi u 
uporabi više od pedeset godina i povezani su s teškom toksičnošću organizma i otpornošću parazita. Prijetnja 
od ove bolesti nije uklonjena unatoč višegodišnjim naporima nekih laboratorija za pronalaženje novih oblika 
liječenja proučavanjem farmakokinetike tripanocida, zatim kombiniranom terapijom, uporabom medicinskog 
bilja te primjenom antioksidansa. Ni razvoj učinkovitog cjepiva nije bio uspješan, zbog antigenskih promjena 
na površinskoj ovojnici tripanosoma. To je smanjilo nade za napredak u razvoju cjepiva, ako ga nije i potpuno 
zaustavilo. Ipak, najnovija istraživanja pokazuju da bi tripanosomski mikrotubulin mogao biti održiv antigen 
za razvoj cjepiva. Ovaj je pregledni članak usredotočen na mjere poduzimane za kontrolu tripanosomoze u 
afričkih životinja kemoterapijom. U njemu se također razmatraju buduće mjere i perspektive s obzirom na to da 
dosadašnje mjere nisu bile uspješne u kontroli bolesti. 
Ključne riječi: kemoterapija; tripanosomoza; mjere kontrole; dvostruko liječenje; kombinirana terapija; 
ljekovito bilje; antigenska varijacija; antigen tubulin________________________________________________________________________________________
